

Index

- abortion, spontaneous, 400, 403, 405
- absorption, 154, 155
- acetazolamide, 175, 183, 239, 262, 312–3, 372
- acne, 272, 274, 276
- ACR (albumin-to-creatinine ratio), 104, 135–136, 227–229
- adherence/nonadherence, 205, 218–225, 239–240, 254, 391–392
- adolescents
 - with BD, 222–223, 363–366, 384–397, 419–420
 - with conduct disorder/aggression, 74–76
- adverse effects, 252
 - of antipsychotics, 213–214, 285–286, 289
 - biomarkers, 255–256
 - cancer (lack of risk), 118–120, 312, 314–315
 - cardiovascular, 267–273
 - dermatological, 273, 275–276
 - dry mouth, 297–298
 - fetal malformations, 7, 13–15, 372–374, 399–404, 420
 - gastrointestinal, 154, 292–294, 301, 396
 - hypercalcemia, 280–281, 282, 306–307
 - hyperparathyroidism, 280–283
 - of lamotrigine, 47
 - leading to discontinuation, 254, 270, 276, 308, 430–431
 - low eGFR, 264–266
- neurological, 300
 - cognitive dysfunction, 303–305
 - EEG pathology, 310
 - fatigue, 306–307
 - idiopathic intracranial hypertension (IIH), 235, 310–312
 - myoclonus, 308–310
 - nystagmus, 299–308
 - parkinsonism, 192, 307–308
 - tremor, 299–303
- in pediatric patients, 395–396
- peripheral edema, 312–313
- renal, 256–257
 - CKD/decreased eGFR, 11–12, 97–98, 110–114, 263
 - microcysts, 116–118
 - interstitial fibrosis, 106
 - polyuria/NDI, 12–13, 98–99, 107–109, 137–141, 257–262
- sexual dysfunction, 276, 289–291
- taste changes, 295–296
- thyroid disorders
 - hyperthyroidism, 276–278
 - hypothyroidism, 8, 16–17, 277, 278–280
- weight gain, 285–288
- see also* neutrophilia; toxicity
- age
 - eGFR decline, 263
 - onset of BD, 222, 364–365, 386
 - see also* children and adolescents; older patients
- aggression, control of, 32–33, 74–76, 241–242
- albuminuria, 98, 104–106, 313
 - monitoring (ACR), 104, 135–136, 7–229
 - stage, 136
- alopecia, 273, 275, 276
- altitude, 186–188, 354–355
- Alzheimer's disease, protective effect of lithium, 11, 32, 65–71, 242, 378–379
- amantadine, 302
- amiloride, 106, 139, 141–144, 182–183, 259, 260–262, 396
- angiotensin II receptor blockers (ARBs), 174–175, 178–179, 261
- angiotensin-converting enzyme inhibitors (ACEIs), 174–175, 178–179, 261
- antacids, 183
- anticonvulsants, 111, 303, 342, 436
- see also* lamotrigine; valproate/divalproex

- antidepressants
 - in BD-1/SAD-BT, 45
 - in BD-2, 2
 - in unipolar MDD, 213
 - SSRIs, 309
- antidiuretic hormone (ADH, vasopressin), 107–109
- antihypertensives, 178–183, 190–191, 261
- antipsychotics
 - in acute mania, 28, 37, 234
 - adverse effects
 - tardive dyskinesia, 213–214
 - weight gain, 285–286, 289
 - in bipolar depression, 45, 56
 - after discontinuation of lithium, 436
 - interactions with lithium, 191–192
 - less effective than lithium for maintenance, 8–10, 49–53, 211–212
 - in unipolar MDD, 213–215
 - in pediatric patients, 388–389, 396
- aquaporins, 107–109
- aripiprazole, 8–9
- arrhythmias, 229, 267–272, 339, 430–431
- atenolol, 302–303
- attention deficit/hyperactivity disorder (ADHD), 384–387, 390–391
- autophagy, 80
- baclofen, 308
- bariatric surgery, 189–190, 288, 355–356
- bedtime, taking lithium at (QHS), 121–123, 152–153, 158–164, 261
- β -blockers, 302–303
- β -catenin, 81–82, 106, 275, 284
- bezafibrate, 125–127
- bicarbonate, 183
- bioavailability, 154–155
- biomarkers
 - for adverse effects, 255–256
 - of response, 56, 217
- bipolar II disorder (BD-2)
 - depression, 2, 29–30, 45–49, 225, 391
 - gradual titration in, 234
 - maintenance therapy, 48–49, 241
 - pediatric patients, 391
 - recurrence when lithium is stopped, 210
- blood pressure, 227–228
- bone health, 283–285
- borderline personality disorder, 74–76
- bradycardia, 267–268, 270, 339
- brain *see* central nervous system
- brain-to-serum (BTS) ratio, 155, 157, 380
- breastfeeding, 409–413, 414–415, 420
- Brugada syndrome, 270–273, 430–431
- CA-BD (child/adolescent BD), 222–223, 363–366, 384–397, 419–420
- Cade, John, 331–332
- caffeine, 184, 301–302
- calcimimetic agents, 276, 281–282, 283
- calcium
 - hypercalcemia, 280–281, 282, 306–307
 - monitoring, 237, 377
- calcium channel blockers, 175, 181–182, 190–191
- cancer risk (lack of impact), 118–120, 312, 314–315
- capacity to consent to/refuse treatment, 266, 435
- carbamazepine, 37–38, 46, 340–341
- carbonate (Li carbonate), 155, 156–157
- carbonic anhydrase inhibitors, 183, 262, 313
- cardiovascular system
 - adverse effects, 267–273
 - fetal malformations, 7, 13, 372–374, 399–404, 420
 - protective effects, 379
 - toxicity, 268, 338, 339
- cariprazine, 8
- central nervous system (CNS)
 - adverse effects, 300
 - cognitive dysfunction, 303–305
 - EEG pathology, 310
 - fatigue, 306–307
 - IIH, 310–312
 - myoclonus, 308–310
 - nystagmus, 299–308
 - parkinsonism, 192, 307–308
 - tremor, 299–303
- brain aging, 67–68
- neuroprotective effect, 11, 32, 73, 242, 378–379
 - mechanisms of action, 71–73, 80, 81–82
- pharmacokinetics, 155, 157, 241, 305–306, 342–343, 380–381
- toxicity
 - acute, 338, 342–343
 - persistent (SILENT), 334, 348–350

Cambridge University Press & Assessment
 978-1-009-22505-2 — The Lithium Handbook: Stahl's Handbooks
 Jonathan M. Meyer, Stephen M. Stahl
 Index
[More Information](#)

INDEX

- cerebrovascular disease, 65–66
- children and adolescents
 - with BD (CA-BD), 222–223, 363–366, 384–397, 419–420
 - with conduct disorder/aggression, 74–76
 - neurodevelopmental effects of fetal exposure, 406–407
- chronic kidney disease (CKD)
 - in BD patients generally, 110
 - and lithium, 11–12, 110–114
 - ESRD, 114–116, 376
 - initiation, 231–232, 233
 - renal microcysts, 116–117
- monitoring *see* estimated glomerular filtration rate (eGFR)
- referral to a nephrologist, 239, 263–264, 377
- staging, 130, 137
- citrate (Li citrate), 154–157, 164–165
- CKD-EPI eGFR equations, 130–132
- Cleaveland, Clarence, 331
- clozapine, 4, 33, 76–77
- cluster headache, 33
- cognitive dysfunction
 - adverse effect of lithium, 303–304
 - and ECT, 351
 - neuroprotective effect of lithium, 11, 32, 65–71, 242, 378–379
- cognitive representation of illness, 218
- collecting duct principal cells, 107, 257, 259–260
- interstitial fibrosis, 106
- polyuria/NDI, 97–99, 107–109
- combination therapies
 - in mania, 37, 389–391
 - in pediatric patients, 389–391
 - in RC-BD, 41–44
- communication
 - with the patient, 205, 218–225
 - with the primary care provider, 227–228, 337, 377
 - see also* counseling
- conduct disorder, 74–76
- congenital malformations, 7, 13–15, 372–374, 399–404, 420
- contraception, 405
- Cooper test dose method, 166–167, 235
- counseling
 - Customized Adherence Enhancement (CAE), 220, 254, 392
 - older patients, 377
 - pediatric patients, 397
 - pregnancy/postpartum, 405, 413
 - prevention of weight gain, 288–289
 - toxicity risk, 337, 341
- creatinine
 - eGFR estimation, 130–132
 - in pregnancy, 190, 408
- creatinine clearance (CL_{CR}), 128, 129
- Customized Adherence Enhancement (CAE), 220, 254, 392
- cystatin C, 128, 130–133
- cysts, renal, 116–117
- death
 - and antipsychotics in unipolar MDD, 214–215
 - lithium toxicity/overdose, 333–334, 340–342
 - sudden cardiac death (SCD), 266–268, 270–272
 - see also* suicidality
- dehydration, 184, 186–187, 353–355, 370, 413
- dementia, protective effect of lithium, 11, 32, 65–71, 242, 378–379
- depression
 - in BD, 31, 45–49
 - BD-2, 2, 29–30, 45–49, 225, 391
 - and hypothyroidism, 279
 - ECT, 351, 352
 - in pediatric patients, 391
 - recurrence after discontinuation, 431
 - unipolar (MDD), 32, 56, 212–215, 242
 - see also* suicidality
- dermatological adverse effects, 272–273, 275–276
- diabetes mellitus medications, 177, 185–186
- dialysis
 - for CKD, 265, 266, 374, 417–419, 420
 - for lithium toxicity, 344, 345–346, 347–348
 - lithium use during, 372, 417
- diarrhea, 186–187, 292–294, 301, 352–354
- dihydropyridines, 181–182
- diltiazem, 181–182, 190–191
- discontinuation of lithium, 224–225, 254, 428–438
- due to adverse effects, 254, 270, 276, 308, 430–431

Cambridge University Press & Assessment
978-1-009-22505-2 — The Lithium Handbook: Stahl's Handbooks
Jonathan M. Meyer, Stephen M. Stahl

Index

[More Information](#)

INDEX

- low eGFR, 264–266
- older patients, 383, 429–430
- slow vs. rapid discontinuation effects, (*see* ch 8)
- recurrence of mood episodes, 210, 431, 433–434
- replacement with other drugs, 436
- and resumption, 431–432, 437–438
- diuretics, 175, 179, 182–184, 313
- in older patients, 181, 381
- treatment of NDI
 - acetazolamide, 175, 183, 239, 262, 312–3, 372
 - amiloride, 106, 142, 182, 259, 261, 396
 - hydrochlorothiazide, 262
- divalproex *see* valproate/divalproex
- dopamine D₂ receptors, 28, 80–81
- potentiation of D₂ antagonists, 191–192, 301
- dosing schedules
 - dialysis patients, 265, 418
- dose prediction, 166–169
 - Cooper test dose method, 166–167, 234–235
- dose reduction due to adverse effects, 296, 301, 302
- frequency and timing
 - pediatric patients, 395, 397
 - QHS (bedtime), 121–123, 152–153, 158–164, 261
 - split doses, 162, 397
 - with/after food, 154, 294, 301
- initiation methods, 36, 234
 - loading, 170–174, 236
- liquid formulations, 155, 164
- in older patients, 377, 380–381
- in pediatric patients, 392–395, 397
- in pregnancy, 406, 412, 414
- and renal function, 120–126
- and surgery, 354
 - bariatric, 189–190, 289, 355–356
- sustained release formulations, 154, 164–165, 173, 293–294, 301
- target levels, 124–125, 241, 377, 396–397
- drug–drug interactions, 174–186, 191–192, 261, 337, 339–340, 381
- drug-induced parkinsonism, 192, 307–308
 - see also* tremor
- dry mouth, 292, 297–298
- dry skin, 274
- early morning urine osmolality (EMUO), 133–134, 139–144, 227–228, 236, 238–239, 256–258
- Ebstein's anomaly, 7, 363, 373, 399–401
- ECG (electrocardiography), 227, 229, 236–237, 266–272, 371
- ECT (electroconvulsive therapy), 336, 350, 351–352
- edema, peripheral, 312–313
- education *see* counseling
- EEG (electroencephalography), 299, 309–310
- efficacy, 8–11, 82–83
 - in acute mania, 28, 37, 377–378
 - aggression reduction, 32–33, 74–76
 - in BD-1, 34–35, 48–56, 388–391, 396
 - in BD-2, 29–30, 45–49
 - in depression
 - BD-1/BD-2, 29–30, 31, 45–49
 - unipolar MDD, 32, 56
 - of neuroprotection, 73
 - neutrophilia, 33, 76–77
 - in older patients, 11, 377–379
 - in pediatric patients, 388–392, 396
 - in rapid cycling BD (RC-BD), 10–11, 30–31, 38–44
 - rehospitalization risk, 27, 51–53
 - on resumption following discontinuation, 431–432, 437–438
 - in schizoaffective disorder, bipolar type (SAD-BT), 29–30
 - in suicidality, 31–32, 57–64, 253–254
- eGFR *see* estimated glomerular filtration rate
- elderly patients *see* older patients
- electrocardiography (ECG), 227, 229, 236–237, 266–272
- electroconvulsive therapy (ECT), 336, 350, 351–352
- electroencephalography (EEG), 299, 309–310
- electrolyte replacement, 187, 353–354
- emotional blunting, 303, 304, 306
- EMUO (early morning urine osmolality), 133–134, 139–144, 227–228, 236, 238–239, 256–258
- ENaC *see* epithelial sodium channel
- end stage renal disease (ESRD), 109, 114–116, 376
 - dialysis, 265, 266, 374, 417–419, 420
- epidemiology, age of BD onset, 222, 364–365, 386

Cambridge University Press & Assessment
 978-1-009-22505-2 — The Lithium Handbook: Stahl's Handbooks
 Jonathan M. Meyer, Stephen M. Stahl
 Index
[More Information](#)

INDEX

- epithelial sodium channel (ENaC)
 renal, 98–99, 107, 182, 259
 on the tongue, 295–296
 equivalence of different formulations and units,
 155, 156–157
 erectile dysfunction, 276, 289–292
 estimated glomerular filtration rate (eGFR), xii,
 128–129
 and CKD stage, 130, 137
 decline, reasons for, 97–98, 113–114, 263
 eGFR_{cr-cys}, 130–133
 in older patients, 263, 369, 376–377
 referral to a nephrologist, 239, 263–264,
 377
 starting lithium, 231–234
 stopping lithium, 264–266
 ethnicity, 130–133
 EXTRIP (Extracorporeal Treatments in Poisoning)
 criteria, 346–348
 eye conditions (nystagmus), 299, 308

 family involvement, 224
 fatigue, 306–307
 fenofibrate, 126
 fetal exposure
 developmental effects, 406–407
 malformations, 7, 13–15, 372–374,
 399–404, 420
 fever and overdose toxicity, 349–350
 fibrates, 125–127
 fluid intake record (FIR), 126, 134, 139, 257
 fluid replacement, 187, 344, 352–354
 focal segmental glomerulosclerosis (FSGS),
 105–106
 folliculitis, 273–274
 food, taking lithium with, 154, 294–295, 301
 fracture risk reduction, 283–285
 furosemide, 181, 381

 gabapentin, 436
 gastrointestinal system
 adverse effects, 154, 292–294, 301, 396
 disorders causing sodium depletion,
 186–187, 352–354
 gemfibrozil, 126
 genetics, 255–256
 glomerular filtration rate (GFR), 129–130
 see also estimated glomerular filtration rate
 (eGFR)
 glomerulus, 100–103
 pathology, 104–106, 135–136
 glucagon-like peptide type 1 (GLP-1) agonists,
 287–288
 glycogen synthase kinase 3- β (GSK3- β), 28, 78,
 80–82, 106, 108–109
 and β -catenin, 81–82, 275, 284
 granulocyte colony stimulating factor (G-CSF),
 76–77
 guidelines for treatment, 35

 hair loss, 274–275
 half-life and steady state, 153–156
 haloperidol, 191–192
 headache, 33, 395
 historical use of lithium, 330–333
 hospitalization
 older patients, 381–383
 recurrence of BD after discontinuation, 210
 rehospitalization risk, 27, 51–53
 for toxicity, 339
 hydrochlorothiazide (HCTZ), 179–183,
 261–262
 hypercalcemia, 280–281, 282, 306–307
 hyperlocomotion, 28
 hyperparathyroidism, 280–283
 hypertension, 227–228
 see also antihypertensives
 hyperthyroidism, 276–278
 hypomania, 29–30
 absence of, perceived as emotional blunting,
 303, 306
 gradual titration of lithium, 234
 as risk factor for dementia, 66–68
 hyponatremia
 leading to lithium toxicity, 186–187,
 352–354
 and other drugs, 179, 181
 hypothyroidism, 8, 16–17, 277, 278–280
 in pregnancy, 406, 414

 idiopathic intracranial hypertension (IIH),
 310–312
 imaging, renal, 116–117
 immune nephritis, 126
 impulsive behavior, reduction, 74–76
 indications for use, vii, 1–2, 33, 210–217
 older patients, 370
 see also efficacy

Cambridge University Press & Assessment
978-1-009-22505-2 — The Lithium Handbook: Stahl's Handbooks
Jonathan M. Meyer, Stephen M. Stahl

Index

[More Information](#)

INDEX

- infants
 - breastfeeding, 409–413, 414–415, 420
 - congenital malformations, 7, 13–15, 372–374, 399–404, 420
- initiation of lithium, 203–234, 243
 - adherence/nonadherence, 205, 218–225, 240
 - how, 234
 - in acute mania, 36, 170–174, 234, 236
 - gradual titration, 234
 - loading method, 170–173, 236
 - test dose method, 166–167, 234–235
 - when, 10, 55, 206–209
 - who, 53–56, 210–217
 - older patients, 377
 - work-up, 231–232
- inositol monophosphatase (IMPase), 78, 80
- interstitial renal fibrosis, 106
- inulin, 129
- kidney *see* renal function
- lactation, 409–413, 414–415, 420
- lamotrigine, 30–31, 46–47, 289
 - maintenance therapy, 48–49
 - suicide risk, 342
- liquid formulations, 155, 156–157, 164
- liraglutide, 287
- lisinopril, 174–178
- lithium carbonate, 155–157
- lithium citrate, 155, 156–157, 164
- lithium orotate, 156–157
- loading protocols, 170–174, 236
- loop diuretics, 178, 181, 381
- Los Angeles County-USC loading protocol, 173–174, 236
- maculopapular rash, 273–274
- magnetic resonance imaging (MRI), renal, 116–117
- maintenance therapy
 - BD-1/SAD-BT, 34–35, 48–56, 189, 241, 242
 - BD-2, 48–49, 241
 - lithium vs. divalproex, 41–44
 - in older patients, 380
 - in pediatric patients, 391, 395, 419–420
 - reduction where adverse effects occur, 296, 301, 302
- major depressive disorder (MDD), 32, 56, 212–215, 242
- mania
 - ECT, 351–352
 - effect on lithium levels, 189
 - efficacy, 37, 388–391
 - combination therapy, 37, 389–391
 - lithium and SGAs compared, 28
 - in older patients, 377–378
 - in pediatric patients, 388–391
 - initiation of therapy, 36, 170–174, 234, 236
 - mechanisms of action, 28, 77–78, 80–81
 - pediatric, 385, 388–391
 - recurrence after discontinuation, 210, 431, 433–434
 - as risk factor for dementia, 66–68
 - target level, 37, 242
- mannitol, 184
- MDD (major depressive disorder), 32, 56, 212–215, 242
- mechanisms of action, 77–78, 83
 - mood stabilization, 28, 77–78, 80–81
 - neuroprotection, 71–73, 80, 81–82
 - neutrophilia, 77
- membranous nephropathy (MN), 105
- metabolic syndrome, 286
- metformin, 287–288
- metronidazole, 177
- minimal change disease (MCD), 105
- minoxidil, 275
- miscarriage, 405
- misconceptions regarding lithium use, 3–17
- monitoring, 236–237
 - of adherence, 239–240
 - after bariatric surgery, 190, 356
 - in breastfeeding dyads, 416, 420
 - of calcium levels, 237, 377
 - of lithium levels
 - frequency, 236–237, 337, 369
 - at initiation of therapy, 237
 - for nonadherence, 240
 - in older patients, 377
 - in overdose, 344
 - POC devices, 164
 - in pregnancy, 405–406
 - in presence of other drugs, 174–178
 - in saliva, 162–164
 - in serum, 158–159

Cambridge University Press & Assessment
 978-1-009-22505-2 — The Lithium Handbook: Stahl's Handbooks
 Jonathan M. Meyer, Stephen M. Stahl
 Index
[More Information](#)

INDEX

- monitoring (*cont.*)
 in older patients, 377
 of patients with low eGFR, 266, 377
 in pregnancy, 405–406
 of renal function, 126–128
 ACR, 104, 135–136, 227–229
 eGFR, 128–129, 231–232, 233, 239, 337, 377
 EMUO (early morning urine osmolality), 133–134, 139–144, 227–228, 236, 238–239, 256–258
 in the first 6 months, 233, 238, 377
 fluid intake, 134, 139, 257
 frequency, 238–239, 337, 369, 377
 in older patients, 377
 referral to a nephrologist, 239, 263–264, 377
 routine protocol, 141–144
 sodium, 179, 181, 261
 of TSH, 237, 377
 lithium toxicity/overdose, 333–334, 340–342
 motor speed, 306–307
 muscular weakness, 306–307
 myoclonus, 308–310

 Na *see* sodium (Na)
 nausea and vomiting, 186–187, 294, 352–354
 nephrogenic diabetes insipidus (NDI), 12–13, 98–99, 107–109, 137–141, 257–262
 EMUO (early morning urine osmolality), 133–134, 139–144, 227–228, 236, 238–239, 256–258
 fluid intake, 134, 139, 257
 perioperative, 354
 stage, 134–135
 treatment, 260–262
 acetazolamide, 183, 262
 amiloride, 106, 142, 182, 259, 261, 396
 hydrochlorothiazide, 262
 nephrotic syndrome, 98, 104–106, 313
 neurodevelopmental effects of fetal exposure, 406–407
 neurological adverse effects, 300
 cognitive dysfunction, 303–305
 EEG pathology, 310
 fatigue, 306–307
 IIH, 310–312
 myoclonus, 308–310
 nystagmus, 299, 308
 parkinsonism, 192, 307–308
 tremor, 299–303
 neuromuscular blockers, 191, 351
 neuroprotective effect, 11, 32, 73, 242, 378–379
 mechanisms of action, 71–73, 80, 81–82
 neurotoxicity
 acute, 338, 342–343
 persistent (SILENT), 334, 348–350
 neutrophilia, 33, 76–77, 298–299
 newborns, 408, 412, 414–415
 see also infants
 NFAT5 (nuclear factor of activated T cells 5), 108–109
 NHE1/NHE3 (Na⁺/H⁺ exchangers), 99, 101–103, 259
 nonadherence/adherence, 205, 218–225, 239–240, 254, 391–392
 nonsteroidal anti-inflammatory drugs (NSAIDs), 176, 178, 184–185
 nystagmus, 299, 308

 obesity, 285–287
 bariatric surgery, 189–190, 288, 355–356
 pretreatment assessment, 228
 olanzapine, 8
 older patients, 366–370, 375–383, 419
 bone health improvement, 283–285
 cardioprotective effects, 379
 discontinuation, 383, 429–430
 dosing and kinetics, 377, 380–381
 drug–drug interactions, 179, 181, 337, 339–340, 381
 efficacy/suitability, 6, 11, 377–379
 mania, 377–378
 monitoring, 377
 need for acute care, 381–383
 neuroprotective effect, 11, 32, 73, 242, 378–379
 renal function, 369, 376–377, 430
 orotate salt, 156–157
 osteoporosis (protective effects), 283–285
 overdose *see* toxicity

 parathyroid dysfunction, 280–283
 Paris dialysis criteria for overdose, 348

Cambridge University Press & Assessment
978-1-009-22505-2 — The Lithium Handbook: Stahl's Handbooks
Jonathan M. Meyer, Stephen M. Stahl

Index

[More Information](#)

INDEX

- parkinsonism, drug-induced, 192, 307–308
see also tremor
- patient counseling/education *see* counseling
- pediatric patients
 - with BD, 222–223, 363–366, 384–397, 419–420
 - with conduct disorder/aggression, 74–76
 - neurodevelopmental effects of fetal exposure, 406–407
- peripheral edema, 312–313
- pharmacokinetics/pharmacodynamics, 151
 - absorption, 154
 - bariatric surgery, 189–190, 288, 355–356
 - in the brain, 155, 157, 241, 305–306, 342–343, 380–381
 - in dialysis patients, 417–418
 - dose prediction, 166–169, 234–235
 - drug–drug interactions
 - lithium toxicity, 337, 339–340, 381
 - pharmacodynamic, 190–192
 - pharmacokinetic, 174–186, 261
 - equivalence of different formulations and units, 155, 156–157
 - half-life/steady state, 153–156
 - high altitude, 186–188, 354–355
 - lithium citrate, 164
 - loading protocols, 170–174, 236
 - in the manic phase, 189
 - in newborns, 414
 - in older patients, 377, 380–381
 - in pediatric patients, 392–395
 - peripheral, 155
 - in pregnancy, 188–189, 407
 - renal clearance/reabsorption, 98, 102–103, 107, 259
 - sustained release formulations, 154, 164–165
 - toxicity, 342–343, 346
 - due to sodium depletion, 186–187, 352–353
 - trough levels and dosing frequency, 121–123, 158–164, 235, 394
- phosphodiesterase 5 (PDE₅) inhibitors, 291
- phosphatidylinositol signaling pathway, 78–80
- pill counts, 240, 391–392
- point-of-care (POC) monitoring devices, 164
- polycystic ovary syndrome (PCOS), 15–16
- polydipsia, psychogenic, 133–135
- polyuria, 7, 12–13, 98–100, 106–109, 137–141, 256–262
 - EMUO, 133–134, 139–144, 227–228, 236, 238–239, 256–258
- fluid intake, 134, 139, 257
 - perioperative, 354
- treatment, 259
 - acetazolamide, 183, 262
 - amiloride, 106, 142, 182, 259, 261, 396
 - hydrochlorothiazide, 262
- postpartum period, 409–413, 414–415, 420
- potassium sparing diuretics, 175, 182
 - amiloride, 106, 142, 182, 259, 261, 396
- pregnancy, 398
 - pharmacokinetics, 188–189, 407
 - postpartum period, 399, 409–413, 414–415, 420
 - renal function, 188–189, 407
 - risk of fetal malformations, 7, 13–15, 372–374, 399–404, 420
 - risk of neurodevelopmental delay, 406–407
- prescribing practices *see* dosing schedules
- preterm birth, 405
- primidone, 303
- propensity score matching, 50–51, 401–403
- propranolol, 302–303
- proteinuria, 98–99, 104–106, 313
 - monitoring (ACR), 104, 135–136, 227–229
 - stage, 136
- proton pump inhibitors (PPIs), 125–126
- psoriasis, 273–275
- psychogenic polydipsia, 133–135
- psychosis
 - postpartum, 409, 413
 - schizophrenia, 29–30
- psychotherapy, 206
- publications, 1–2
- QHS dosing, 121–123, 152–153, 158–164, 261
- quetiapine, 8–10, 49–50
- race in older eGFR formulas, 130–133
- rapid cycling bipolar disorder (RC-BD), 6, 10–11, 30–31, 38–44, 217
- recurrence of mood episodes (after discontinuation), 210, 431, 433–434

Cambridge University Press & Assessment
978-1-009-22505-2 — The Lithium Handbook: Stahl's Handbooks
Jonathan M. Meyer, Stephen M. Stahl

Index

[More Information](#)

INDEX

- referral to a nephrologist, 239, 263–264, 377
- refusal of treatment, 205, 219, 435
 - see also* discontinuation of lithium
- renal function, xi–xiii, 95
 - adverse effects of lithium, 256–257
 - albuminuria, 98, 104–106, 313
 - CKD/decreased eGFR, 11–12, 97–98, 110–114, 263
 - cysts, 116–117
 - interstitial fibrosis, 106
 - lack of association with cancer, 118–120, 314
 - polyuria/NDI, 12–13, 98–99, 107–109, 137–141, 257–262
 - adverse effects of other drugs, 125–126
 - anatomy and physiology, 100–102
 - cardiometabolic comorbidities in BD patients, 11–12, 97, 110, 263
 - dialysis patients taking lithium, 265, 266, 374, 417–419
 - dosage of lithium, 120–126
 - frequency and timing, 121–123, 160
 - high therapeutic levels, 124–125
 - drug–drug interactions, 174–186, 261
 - initiating lithium, 231–232, 377
 - monitoring, 126–128
 - ACR, 104, 135–136, 227–229
 - breastfeeding dyads, 416
 - eGFR, 128–133, 227–240, 335–336, 368–376
 - EMUO, 133–134, 139–144, 227–228, 236, 238–239, 256–258
 - in the first 6 months, 233, 238, 377
 - fluid intake, 134, 139, 257
 - frequency, 238–239, 369, 377
 - in older patients, 369, 377
 - referral to a nephrologist, 239, 263–264, 377
 - routine protocol, 141–144
 - sodium, 179, 181, 261
 - in older patients, 369, 376–377, 430
 - pharmacokinetics, 98, 259
 - collecting duct, 107
 - glomerulus/loop of Henle, 102–103
 - in pregnancy/postpartum, 188–189, 407, 416
 - referral to a nephrologist, 239, 263–264, 377
 - staging
 - albuminuria with ACR, 136, 138
 - CKD, 130, 137–138
 - NDI, 134–135
 - risperidone, 8, 388–389
 - saline, intravenous for overdose, 342–344
 - salivary levels, 162–164
 - SCD *see* sudden cardiac death
 - schizoaffective disorder, bipolar type (SAD-BT), 2
 - discontinuation, 224–225
 - efficacy
 - depression, 45
 - mania, 29–30
 - maintenance therapy, 241, 242
 - recurrence when lithium is stopped, 210
 - schizophrenia, 29–30
 - second generation antipsychotics *see* antipsychotics
 - seizures, 310
 - self-harm *see* suicidality
 - semaglutide, 287–288
 - serum levels *see* target levels
 - sexual dysfunction, 276, 289–291
 - SGA (second generation antipsychotics) *see* antipsychotics
 - sick sinus syndrome, 270 (*see* bradycardia)
 - side effects *see* adverse effects
 - sildenafil, 291–292
 - SILENT (syndrome of irreversible lithium-effectuated neurotoxicity), 334, 348–350
 - skin and hair problems, 273, 275–276
 - sleep deprivation, 413
 - sodium (Na)
 - depletion leading to toxicity, 186–187, 352–354
 - monitoring, 179, 181, 261
 - myocardial voltage-dependent channels (I_{Na}), 267–268
 - renal transport
 - drug–drug interactions, 178, 179, 182, 183
 - ENaC, 98–99, 107, 182, 259
 - Na^+/H^+ exchangers (NHE1/NHE3), 99, 101–103, 259
 - Na^+/K^+ ATPase, 103
 - tongue ENaC channels, 295–296
 - sodium-glucose cotransporter 2 (SGLT-2)
 - inhibitors, 177, 185–186

Cambridge University Press & Assessment
 978-1-009-22505-2 — The Lithium Handbook: Stahl's Handbooks
 Jonathan M. Meyer, Stephen M. Stahl

Index

[More Information](#)

INDEX

- spironolactone, 182
- SSRIs (selective serotonin reuptake inhibitors), 309
- steady state and half-life, 153–156
- stopping lithium *see* discontinuation of lithium
- stroke, 65–66
- sudden cardiac death (SCD), 266–268, 270–272
 - Brugada syndrome, 270–273
- suicidality
 - after discontinuation, 433
 - efficacy, 31–32, 57–64, 253–254
 - lithium overdose, 340–342
 - non-BD patients, 241–242
 - see also* depression
- surgery
 - bariatric, 189–190, 288, 355–356
 - for hyperparathyroidism, 281, 283
 - neuromuscular blockers, 191, 351
 - toxicity risk, 337, 354, 355
- sustained release formulations, 154, 164–165, 173, 293–294, 301
- sweating, excessive, 352–353
- sympathomimetics, 301–302
- tardive dyskinesia, 213–214
- target levels, 124–125, 241
 - acute mania, 37, 242
 - BD-2, 48–49, 241
 - in older patients, 377
 - in pediatric patients, 396–397
- taste, changes in, 295–296
- telomere length, 73
- teratogenic risks, 7, 13–15, 372–374, 399–404, 420
- test dose methods, 166–168, 234–235
- thiazide-type diuretics, 176, 179–181, 183, 262
- thyroid function
 - hyperthyroidism, 276–278
 - hypothyroidism, 8, 16–17, 276–277, 278–280
 - in pregnancy, 406, 414
- thyroid stimulating hormone (TSH), 227, 229, 236–237, 277–279, 371
 - in pediatric patients, 395, 396
 - in pregnancy/postpartum, 406, 416
- topiramate, 303
- toxicity, 329–330
 - cardiovascular, 268, 338, 339
 - causes and risk factors, 334–335, 339–340
 - drug interactions, 178–181, 184–185, 375–376, 381
 - sodium depletion, 186–187, 352–354
 - suicidality, 340–342
- CNS dysfunction
 - acute, 338, 342–343
 - persistent (SILENT), 334, 348–350
- early research, 330–333
- and ECT, 336, 350, 351–352
- fatal, 333–334
- high altitude, 186–188, 354–355
- incidence, 334
- management
 - assessment and monitoring, 337, 342–343, 344, 356
 - dialysis, 344, 345–346, 347–348
 - fluids, 187, 343–344, 353–354
 - location (inpatient/outpatient), 339
- older patients, 381
- patterns of overdose, 333–334, 338, 344, 346
 - lithium naive patients, 342–343
- prevention, 337
- signs and symptoms, 296, 337–338, 342–343
- and surgery, 337, 354, 355
 - bariatric, 189–190, 355–356
- tremor, 299–303
 - see also* drug-induced parkinsonism
- trends in lithium use, 3, 26
- triarterene, 182
- trough levels, 121–123, 158–159, 235, 394
- TSH *see* thyroid stimulating hormone
- tumors, 118–120, 314–315
- units (mEq and mg), 156–157
- urinary output *see* polyuria
- valproate/divalproex (VPA)
 - contraindicated in childbearing women, 14–15
 - loading, 170
 - in mania, 37–38
 - in pediatric patients, 387
 - in rapid cycling (RC-BD), 41–44
 - suicide risk, 341
 - weight gain, 286

INDEX

- vasopressin (antidiuretic hormone), 107–109
- verapamil, 190–191
- vomiting and nausea, 186–187, 294, 352–354
- weight gain, 285–288
 - bariatric surgery, 189–190, 288, 355–356
 - pretreatment assessment, 228
- women (of reproductive age)
 - PCOS, 15–16
 - pregnancy/postpartum *see* pregnancy
- xerostomia (dry mouth), 297–298
- younger patients *see* children and adolescents